As of 2025-12-31, the Relative Valuation of TCR2 Therapeutics Inc (TCRR) is (50.89) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.48 USD, the upside of TCR2 Therapeutics Inc based on Relative Valuation is -3538.4%.
The range of the Relative Valuation is (36.89) - (64.64) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 15.6x | 12.2x |
| Forward P/E multiples | 8.9x - 15.7x | 12.3x |
| Fair Price | (36.89) - (64.64) | (50.89) |
| Upside | -2592.5% - -4467.5% | -3538.4% |
| Date | P/E |